Document is current
Any future updates will be listed below
-
Authors
Price, Nathan L https://orcid.org/0000-0002-2821-9608
Goedeke, Leigh
Suárez, Yajaira https://orcid.org/0000-0003-4549-2953
Fernández‐Hernando, Carlos https://orcid.org/0000-0002-3950-1924
-
Funding
Funding for this research was provided by:
HHS|NIH|National Heart, Lung, and Blood Institute (R35HL135820)
HHS|NIH|National Heart, Lung, and Blood Institute (R01HL135012)
HHS|NIH|National Heart, Lung, and Blood Institute (R01HL105945)
HHS|NIH|National Heart, Lung, and Blood Institute (K99HL150234)
HHS|NIH|National Institute of Diabetes and Digestive and Kidney Diseases (1K01DK120794)
American Heart Association (16EIA27550005)
- License Information
-
More Information
Article History
Received: 17 September 2020
Revised: 30 January 2021
Accepted: 3 February 2021
First Online: 3 May 2021
Conflict of interest
: Carlos Fernández‐Hernando and Yajaira Suárez have a patent on the use of miR‐33 inhibitors to treat inflammation. The other authors report no conflicts.
